drug
paclitaxel albumin bound
Marketedupdated 3mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugpaclitaxel36 co-mentions · 27 sources
- drugSOR-00736 co-mentions · 27 sources
- tagAdCom28 co-mentions · 25 sources
- tagPMA Approval28 co-mentions · 25 sources
- company$BSXBOSTON SCIENTIFIC CORP5 co-mentions · 5 sources
- tagOncology3 co-mentions · 1 sources
- companyBaxter Healthcare Corp1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 109 investigational indications.
indications
investigational
NSCLCBreast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying paclitaxel albumin bound
- phase3Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- phase2Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
- phase2To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- phase2ATEMPT 2.0: Adjuvant T-DM1 vs TH
- phase2A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
- phase3Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
- phase3An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
- phase3A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 21, 2026
1 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jul 12, 2034patentUS 9511046*PED
- Jan 12, 2034method-of-use (U-1434)US 9511046
- Sep 4, 2032patentUS 9393318*PED
- Sep 4, 2032patentUS 9597409*PED
- Mar 4, 2032method-of-use (U-1290)US 9393318
- Mar 4, 2032method-of-use (U-1290)US 9597409
- Feb 13, 2027patentUS 8034375*PED177d
- Aug 21, 2026patentUS 7758891*PED1d
- Aug 21, 2026patentUS 8268348*PED1d
- Aug 21, 2026patentUS 9101543*PED1d
- Aug 13, 2026method-of-use (U-1290)US 8034375
- Feb 21, 2026method-of-use (U-1434)US 7758891
- Feb 21, 2026method-of-use (U-1290)US 8268348
- Feb 21, 2026method-of-use (U-1434)US 9101543
News(10)
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.stat · 2mo ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 3mo ago
- Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 3mo ago
- Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.onclive · 3mo ago
- Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLLore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.onclive · 3mo ago
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 3mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 3mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 3mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 3mo ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that